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ABSTRACT 
 
 
The first detailed study of intramolecular aza-Prins and aza-silyl-Prins reactions, starting from acyclic materials, are 
reported.  The methods allow rapid and flexible access towards an array of [6,5] and [6,6] aza-bicycles, which form the 
core skeletons of various alkaloids.  Based upon our findings on the aza-Prins and aza-silyl-Prins cyclisations, herein we 
present simple protocols for the intramolecular preparation of the azabicyclic cores of the indolizidines and 
quinolizidines using a one pot cascade process of N-acyliminium ion formation followed by aza-Prins cyclisation and 
either elimination or carbocation trapping.  It is possible to introduce a range of different substituents into the 
heterocycles through a judicial choice of Lewis acid and solvent(s), with halo-, phenyl- and amido- substituted 
azabicyclic products all being accessed through these highly diastereoselective processes. 
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INTRODUCTION 
Azabicyclic compounds are ubiquitous in nature, with the quinolizidine and indolizidine alkaloids being prime examples, 
and which possess a wide range of biological activities.  The polyhydroxylated indolizidine alkaloids, such as (+)-
castanospermine, have attracted particular attention as glycosidase inhibitors, as well as demonstrating anti-viral (in 
particular anti-HIV), antitumour and immunomodulation activities.  These properties continue to drive the search for 
novel synthetic approaches towards their preparation.  Herein we report a novel and highly efficient cascade process 
for the rapid synthesis of azabicycles. 
 
Figure 1. Representative fused azabicycles 
 
 
We have had a long standing interest in the Lewis acid-promoted Prins reaction1,2 and have, along with others, more 
recently reported on the nitrogen equivalent of this reaction, the aza-Prins reaction,3-12 together with its silicon 
modified counterpart the aza-silyl-Prins reaction.2,13-16  Both reactions involve the intermolecular reaction of a carbonyl 
or related compound (aldehyde, ketone or epoxide) with a secondary homoallylic amine in order to form an iminium 
ion, which then undergoes intramolecular Prins cyclisation to give either piperidines or tetrahydropyridines, depending 
on the absence or presence of the silicon moiety on the alkene (Scheme 1).  The aza-silyl-Prins reaction is highly tolerant 
of a range of groups on the secondary amine, but is more limited to a sulfonamide in the aza-Prins reaction. 
 
Scheme 1. The aza-Prins6,17-19 and aza-silyl-Prins2,13,14 reactions 
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It occurred to us that it may be possible to access the azabicyclic core of various alkaloids by a two-step one-pot cascade 
process, first involving intramolecular iminium ion formation, followed by Prins cyclisation and either carbocation 
trapping by a suitable nucleophile or elimination from the resultant carbocation (Scheme 2). Reddy20, Saikia21,22, 
Overman23 and Waters24 have all prepared azabicyclic systems using a Prins or related cyclisation process, but have 
either started from an intact or commercial mono-cyclic system,24 or have required the sequential formation and 
purification of the mono-cyclic precursors, followed by a second cyclisation process.23  Thus the uniqueness and 
advantage of this approach in the one-pot double cyclisation, forming both rings in a single transformation. 
 
Scheme 2. Previous related work and proposed cascade process 
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RESULTS AND DISCUSSION 
In attempting to make the desired cyclisation precursors, we quickly established that the presence of both an 
aldehyde and amine in the same precursor was problematic, and that they reacted together before the desired cascade 
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sequence.  Therefore an acetal was considered as a viable alternative.  To test the feasibility of using an acetal in an 
aza-silyl-Prins reaction, 1,1-dimethoxyhexane 2 was reacted with (Z)-N-benzyl-4-(trimethylsilyl)but-3-en-1-amine 1 and 
gave the corresponding tetrahydropyridine 3 in good yield (Scheme 3). 
 
Scheme 3. Aza-silyl-Prins reaction using 1,1-dimethoxyhexane 
 
 
Therefore with the strategy of using an acetal in mind, both the required secondary amine and amide precursors were 
prepared using related routes.  It was envisaged that the cyclisation precursors could be obtained by two possible 
routes, namely amine displacement of a suitably activated homoallylic alcohol or peptide coupling of a homoallylic 
amine with a carboxylic acid. 
The former method was examined first, with 5,5-dimethoxypentylamine 4 prepared in four steps and in 80% overall 
yield from 5-aminopentanol (Scheme 4a).  (Z)-4-(Trimethylsilyl)but-3-en-1-yl 4-toluenesulfonate 6 was obtained from 
3-butyn-1-ol via (Z)-4-(trimethylsilyl)but-3-en-1-ol 5.  Unfortunately, all attempts at coupling these two compounds 
failed to give the desired cyclisation precursor, with the product of amine dialkylation being the main product obtained. 
The latter amide coupling approach was then examined.  The two prerequisite amines 7 and 8 were prepared from 
the corresponding alcohols, namely 3-buten-1-ol and (Z)-4-(trimethylsilyl)but-3-en-1-ol 5, by tosylation, displacement 
with azide and reduction with lithium aluminium hydride in 70% (5 steps from 3-butyn-1-ol) and 74% (from 3-buten-1-
ol) overall yields respectively (Scheme 4b).  8 could also be prepared quantitatively using Mitsunobu chemistry with 
phthalimide followed by cleavage using hydrazine monohydrate. 
4,4-Dimethoxybutanoic acid 9 was prepared in two steps from methyl 4-nitrobutanoate via a Nef reaction followed 
by basic methanolysis, in 86% overall yield (Scheme 4c).  5,5-Dimethoxypenanoic acid 10 was also prepared in two steps 
by ozonolysis of cyclopentene followed by methanolysis, in 47% overall yield (Scheme 4d). 
 
Scheme 4. Synthesis of cyclisation precursors. 
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Two methods were employed for the amide coupling reactions (Scheme 5).  Acids 9 and 10 were activated with N-
hydroxysuccinimide prior to coupling the active esters with either amine 7 or 8 using N,N-dicyclohexylcarbodiimide.  
Alternatively, the peptide coupling reagent n-propane phosphonic acid cyclic anhydride, T3P®,25 was also successfully 
employed for the direct coupling of the acids and amides, albeit in slightly lower yields, but with the advantage that 
purification was achieved by simple aqueous extraction.  Finally, the secondary amines 15 and 16 were prepared by 
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lithium aluminium hydride reduction of the amides 11 and 13.  But-3-ynylamine was prepared from 3-butyn-1-ol by 
tosylation, azide displacement and LiAlH4 reduction and the T3P® method again used to prepare the alkynyl derivatives 
17 and 18.  Thus all the required linear cyclisation precursors could be obtained easily and in high overall yields. 
 
Scheme 5. Synthesis of cyclisation precursors. 
 
 
We have previously reported the use of indium trichloride in acetonitrile at reflux as being highly effective for 
promoting the aza-silyl-Prins reaction with aldehydes2,3,13,14 and indeed this was successful in promoting an 
intermolecular aza-silyl-Prins reaction with an acetal (Scheme 3).  However, these conditions failed to give any of the 
desired aza-bicycle when secondary amines 15 or 16 were employed, with starting material recovered.  Changing the 
solvent to toluene, and heating at reflux, gave traces of product but rapid decomposition of the starting material was 
observed, at a rate considerably faster than the cyclisation.  The addition of 4Å molecular sieves did not influence the 
outcome of the reaction.  It is postulated that the Lewis acid may be complexing with the amine rather than activating 
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the acetal, preventing the first cyclisation occurring.  Thus indium trichloride is seen as a promoter of the intermolecular 
aza-Prins reaction with acetals, but a “poison” of an intramolecular variant. 
The same Lewis acid screening was then applied to the aza-silyl-Prins reaction amide precursors 13 and 14.  Gratifyingly, 
double cyclisation now took place relatively easily with a number of Lewis acids, with the [6,5] and [6,6] bicycles being 
obtained in good yield, particularly when employing scandium triflate (Table 1 entries 2 & 5) and indium triflate (Table 
1 entries 1 & 4) as Lewis acids. 
 
Table 1. Iminium ion formation/Aza-Prins cyclisation cascades 
 
 n Lewis Acida Product % Yieldb 
1 1 In(OTf)3 19 32 
2 1 Sc(OTf)3 19 75 
3 1 InCl3 19 17 
4 2 In(OTf)3 20 60 
5 2 Sc(OTf)3 20 64 
6 2 InCl3 20 traces 
aAll reactions were performed at reflux temperature; bpurified, isolated yields. 
 
Given that numerous indolizidine and quinolizidine alkaloids (Figure 1) are poly-hydroxylated, frequently at the 
positions of the alkene produced in 19 and 20, attempts were made to perform an Upjohn OsO4/NMO dihydroxylation 
reaction on the [6,5] product 19 (Table 1 entry 2).  With no starting material or product isolated, the reaction was 
repeated in d6-acetone/D2O (9:1) and monitored by NMR: the complete disappearance of the olefin signals at  = 5.77 
and 5.67 was observed, and two new multiplet signals at  = 3.71 and 3.85 appeared (for 2 x CH(OH)), indicating the 
formation of two hydroxyl groups.  Unfortunately, the diol was found to be very water soluble and could not be 
extracted and purified after destruction of the osmate ester.26  Attempts to capture the diol as either the acetate (using 
acetyl chloride) or 4-nitrobenzoate ester (from 4-nitrobenzoyl chloride) both failed.  An identical outcome was observed 
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when using 20: when the reaction was followed by 1H NMR, the two alkene peaks at  = 5.81 and 5.50 rapidly 
disappeared to be replaced by multiplets at  = 3.74 and 4.01, but again the product was completely water soluble. 
 
With a successful aza-silyl-Prins route into the indolizidine and quinolizidine cores to hand, attention turned to utilizing 
the aza-Prins reaction to a similar end.  As shown in Table 2, a number of Lewis acids were highly efficient at promoting 
the double cyclisation: iron trichloride, indium trichloride and indium tribromide were all highly successful promoters 
and provided a nucleophile for capture.  Iron trichloride also gave the best diastereomeric ratios, ca. 9:1 (Table 2 entries 
1 & 8).  The yields of the [6,6] system with any particular Lewis acid were generally higher than the equivalent [6,5] 
system with the same Lewis acid under identical conditions.  Intriguingly, when using Lewis acid triflates and boron 
trifluoride, a mixture of two inseparable unsaturated products 23a & 23b was isolated as the major product, along with 
small amounts of the fluoride-trapped adduct.  In all cases, diastereomeric ratios were measured from the reaction 
mixture by comparing the integration of the signals for the C(5)H2 (6,5 adduct) or C(6)H2 (6,6), which were clearly 
separate in each diastereoisomer (Figure 2).  NOE values consistently identified the major adduct in both the (6,5) and 
(6,6) systems as the cis product. 
 
Figure 2. Diastereomeric ratio determination and NOE measurements for 21a (Table 2 entry 2), clearly showing d.r.=4:1 
from integration of peaks for H-C(5) at  = 4.16:4.03 and 3.13:2.66 
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Table 2.  Iminium ion formation/Aza-Prins cyclisation cascades 
 
 n Lewis 
Acida 
Solvent Product % Yieldb 
(X=) 
d.r.c % Yield 
23a+b 
(mixture)b 
1 1 FeCl3 CH2Cl2 21a 94 (Cl) 9:1  
2 1 InCl3 CH2Cl2 21a 45 (Cl) 4:1  
3 1 BBr3 CH2Br2 21b 51 (Br) 4:1  
4 1 InBr3 CH2Br2 21b 16 (Br) 4:1  
5 1 BF3.OEt2 CH2Cl2 21c Traces (F) 1:1 43 
6 1 In(OTf)3 CH2Cl2 21a 6 (Cl) - 7 
7 1 In(OTf)3 MeCN  0 - 5 
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8 2 FeCl3 CH2Cl2 22a 86 (Cl) 9:1 - 
9 2 InCl3 CH2Cl2 22a 64(Cl) 7:3 - 
10 2 InBr3 CH2Br2 22b 96 (Br) 7:3 - 
11 2 BF3.OEt2 cHex 22c 25 (F) 1:1 32d 
aAll reactions were performed with 1 equiv. Lewis acid and at reflux temperature; bpurified, isolated yields. cd.r.’s were 
determined by NMR integration of the signal for C(5)H2 or C(6)H2. dAn additional third unsaturated product 23c was 
also observed just in this particular reaction. 
 
 
When using 1 equiv. InBr3 (Table 2 entry 4), an intriguing product that is indicative of half-cyclisation, was also isolated.  
This leads us to postulate on the mechanism of the double cyclisation process (Scheme 6).  It is thought that first, 
intramolecular Lewis acid-promoted acyl iminium ion (24) formation takes place.  This process is followed by an 
intramolecular aza-Prins cyclisation, to give the secondary cyclic carbocation (25).  The ultimate reaction product is 
then dependent upon the nature of the substituent on the alkene in the starting material.  When this was a Z-vinylsilane 
(terminal TMS group), the carbocation is presumably stabilised by the -effect from silicon, and elimination occurs to 
give the single alkene product (19 or 20), with no regioisomers.  However, when the alkene was un-substituted, there 
is no such stabilisation or favourable elimination reaction that can take place, so an external nucleophile, normally from 
the Lewis acid, is trapped by the carbocation (21 or 22).  An exception to this can be found in Table 2 entry 4, where 
several additional products were observed in addition to the desired product: the intramolecular acyliminium ion is 
trapped by the methoxide anion giving 26.  It is highly likely that this remained as part of a tight ion pair during the 
oxonium ion formation/cyclisation to acyliminium ion process, and thus trapping was facile, although this product has 
not been observed in any other attempted double cyclisation.  The addition of 1 equiv. of InBr3 to the methoxy-
intermediate provided bicycle 21b in quantitative yield (Scheme 6).  This problem of incomplete cyclisation could 
therefore be overcome by employing greater than 2 equiv. of Lewis acid in the reaction.  Since all reactions in Table 2 
were performed with 1 equiv. of Lewis acid, this suggests that some Lewis acids are able to promote the first cyclisation 
but not the second.  The best yields obtained in Table 2 for the ‘double cyclisation approach’ are far superior to any 
two-step sequential cyclisation approach to the same targets. 
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Scheme 6. Proposed mechanism and origin of stereochemical outcome for the aza-silyl-Prins and aza-Prins 
cyclisations. 
 
Thus overall, the examples presented in Tables 1 and 2 and Scheme 6 may be considered as N-acyliminium ion-type 
cyclisations, given that the double cyclisation did not proceed when Y = 2xH (Scheme 2).  Acyliminium ion cyclisations 
have been comprehensively reviewed27,28 and these reviews cover many related examples of bicycle formation where 
one ring is already in place, and the second is formed via an acyliminium cyclisation (Scheme 2).  However, Hart has 
reported the only related example of a double cyclisation, employing formic acid as the promotor of a double 
cyclisation29 in the total synthesis of the Lythracaeae alkaloids Lythrancepine II and III.30,31 
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Given Martín’s success in the Prins cyclisation of alkynes,4,32 we investigated the intramolecular cyclisation of precursors 
17 and 18.  Neither gave products of double cyclisation.  Cyclisation of 17 gave two products, 28 and 29, derived from 
the initial cyclisation but no subsequent Prins reaction and 18 gave a complicated mixture from which no compounds 
could be characterised. 
 
Scheme 7. Attempted alkyne aza-Prins reaction 
 
 
The incorporation of alternative nucleophiles, in place of the anion from the Lewis acid, during a Prins cyclisation has 
been reported and is an attractive feature of the reaction.17,33-35  This also adds a further layer of complexity to the 
cascade process, making it now three sequential steps: following cyclisation/iminium ion formation and aza-Prins 
cyclisation, the transformation may be terminated with Friedel-Crafts or Ritter reaction.  In general, the trapping of an 
external nucleophile occurs most readily when employing a Lewis acid poor in providing an anion for capture.  With 
this in mind, the double cyclisation was attempted using boron trifluoride, which had been shown to be poor itself at 
supplying a nucleophilic anion, with the aim that the solvent may be incorporated favourably and rapidly instead (Table 
3). 
 
Table 3.  Capturing alternative nucleophiles during the double cyclisation. 
 
 n Solvent sol = Product % Yielda Product % Yieldb 
1 1 PhH Ph 30a 20 21c 36 
2 1 MeCN NHAc 30b 2 (NHAc) 21c Traces 
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30c 40 (NH2) 
3 1 EtOAc OAc 30d 40 21c 4 
4 2 PhH Ph 31a 23 22c 33 
5 2 MeCN NHAc 31b 1 22c 2 
6 2 EtOAc OAc 31c 
31d 
4 (OAc) 
5 (OH) 
22c 20 
aisolated and purified yield of solvent-trapped adduct; bisolated and purified yield of F-containing product 
 
Both Prins-Friedel-Crafts (entries 1 & 4) and Prins-Ritter (entries 2 & 5) reactions proceeded in modest yields, in both 
[6,5] and [6,6] systems.  Surprisingly, the O-acetyl group, from ethyl acetate, was also found to incorporate in modest 
yield (entries 3 & 6).  Pleasingly, the OAc trapped indolizidine (entry 3) was obtained as a single diastereoisomer in 
crystalline form (Figure 3), confirming the proposed stereochemistry from the NMR data. 
 
Figure 3. 3-oxooctahydroindolizin-7-yl acetate 30d.  Displacement ellipsoids are drawn at the 50% probability level. 
 
 
 
CONCLUSIONS 
In conclusion, we have shown that both the aza-Prins and aza-silyl-Prins reactions may be utilised for the preparation 
of azabicycles, the core structure for accessing indolizidine and quinolizidine alkaloids.  The current approach offers a 
number of advantages over existing methods for accessing the same architectures, namely good yields, starting from 
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acyclic precursors and the ability to incorporate a range of nucleophiles in the bicyclic products. The Lewis acids FeCl3 
(for n=1) and FeCl3, InCl3 and InBr3 (for n=2) were particularly efficient at promoting double cyclisations. The scope and 
limitations of these reactions with respect to additional substituents and applications, will be reported in due course. 
 
EXPERIMENTAL SECTION 
GENERAL DETAILS 
Commercially available reagents were used as supplied.  All solvents were pre-dried prior to use.    All reactions 
were carried out under anhydrous conditions unless otherwise stated, and all glassware, syringes and needles 
were oven-dried and then allowed to cool prior to use in experiments.  Infrared spectra were recorded in the 
range 4000-600 cm-1, obtained directly as either solids or neat liquids. Chemical shifts in 1H NMR spectra are 
reported in δ (ppm) relative to residual solvent signals CDCl3 δH = 7.26 ppm; δC = 77.23 ppm or d6-DMSO δH = 2.50; 
δC = 39.51.  Multiplicities of signals are reported using standard abbreviations: s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet, b = broad. Coupling constants (J) are reported in hertz.  Low resolution masses were 
recorded in EI mode incorporating an SL Ion Trap.  High resolution mass spectra were recorded using a LTQ 
Orbitrap XL with resolution up to 100,000 (FWHM).  Fourier Transform mass spectrometry was performed for 
HRMS measurements. 
 
General Procedure 1: Tosylation of alcohols (on 35 mmol scale) 
To a cooled solution of homoallyl alcohol or penten-1-ol (1 equiv.) in CH2Cl2 (2 mL per mmol) were added DMAP 
(0.6 equiv.) and p-TsCl (1.2 equiv.) at 0 °C. Et3N (1 equiv.) was then added dropwise and the solution was stirred 
at 0 °C until TLC analysis showed complete consumption of the starting alcohol. The solution was diluted with Et 2O 
(2 mL per mmol) and stirred for another 30 min. Precipitated solid was removed by filtration and the re sulting 
solution washed with 10% aqueous copper sulfate solution (2 x 1.1 mL), followed by 15% aqueous NaHCO 3 solution 
(1.1 mL) and finally brine (0.9 mL per mmol). The organic phase was dried (MgSO 4), filtered, and volatile 
components were removed under reduced pressure and the residue purified by flash column chromatography 
(PE:Et2O 1:1) to yield the tosylated alcohol. 
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General procedure 2: Coupling reaction by T3P® (on 3 mmol scale) 
To a stirred solution of 4,4-dimethoxybutanoic acid 6 or 5,5-dimethoxypentanoic acid 7 (1 equiv.) and T3P® (1.15 equiv.) 
in dry EtOAc (8 mL per mmol) were added sequentially Et3N (2 equiv.) and (Z)-4-(trimethylsilyl)but-3-en-1-amine 4 or 
3-buten-1-amine 5 (1 equiv.). After complete consumption of the starting acid was detected by TLC analysis, the mixture 
was acidified to pH 7 by the addition of 1.0 M aqueous HCl and the product was extracted into EtOAc (10 mL per mmol). 
The organic layer was washed with water (2 x 10 mL per mmol) followed by brine (10 mL per mmol), dried (MgSO4) and 
the volatiles removed under reduced pressure to yield the desired amide, which was used without further purification. 
 
General procedure 3:  Azidation of tosylated alcohol (on 120 mmol scale) 
NaN3 (3 equiv.) was added portionwise to but-3-en-1-yl toluene-4-sulfonate or (Z)-4-(trimethylsilyl)but-3-en-1-yl 
4-toluenesulfonate (1 equiv.) in DMF (2 mL per mmol). The resulting solution was heated and stirred to 60 °C for 
2 h. After cooling to rt, the mixture was poured into a solution of Et2O:H2O (7 mL per mmol, 3:7, v/v). After stirring 
for 30 min, the aqueous layer was separated, and the organic layer extracted with water (3 x 1  mL per mmol). The 
aqueous layer was combined with the aqueous extracts and this was extracted with Et 2O (3 x 1.3 mL per mmol) 
and the combined organic extracts were washed with saturated aqueous LiCl (1.3 mL per mmol) and brine (1.3 mL 
per mmol). The resulting organic solution was dried (MgSO4), filtered, the solution was concentrated under 
reduced pressure and the residue subjected to flash column chromatography (PE:Et2O 9:1) to yield the pure azide. 
 
General procedure 4: Intramolecular aza-silyl-Prins reaction (on 0.70 mmol scale) 
To a Lewis acid (1 equiv.) suspension in MeCN (3.5 mL per mmol) heated to reflux was added a solution of (Z)-4,4-
dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)butanamide 10 or (Z)-5,5-Dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-
yl)pentanamide 11 (1 equiv.) in MeCN (1.5 mL per mmol) dropwise over 1 min. The mixture was stirred at reflux 
for 48 h or until GC-MS analysis showed complete disappearance of the amide peak. The solution was cooled to 
rt, poured into a biphasic solution of CH2Cl2 (4 mL per mmol) and water (8 mL per mmol) and stirred for 30 min. 
The organic layer was separated, the aqueous layer extracted with CH2Cl2 (3 x 2 mL per mmol). Combined organic 
layers were washed with brine (4 mL per mmol), dried (MgSO4), filtered and volatiles were evaporated under 
reduced pressure and purification by flash column chromatography yielded the unsaturated N-fused bicycle. 
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General procedure 5: Intramolecular aza-Prins reaction (on 1 mmol scale) 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide 8 or N-(but-3-en-1-yl)-5,5-dimethoxypentanamide 9 (1 equiv.) was mixed 
with the solvent (3.5 mL per mmol) for 5 min and the Lewis acid (1 equiv.) was added. The mixture was stirred for 48 h 
or until GCMS analysis showed complete disappearance of the amide. Water (5 mL per mmol) was added to quench 
the reaction and the mixture was stirred for 30 min. The organic layer was separated, and the aqueous layer extracted 
with solvent (3 x 4 mL per mmol). The combined organic solutions were washed with brine (4 mL), dried (MgSO4), 
filtered, and volatile components were evaporated under reduced pressure. Purification of the residue by flash column 
chromatography yielded the bicyclic derivative. 
 
 
1. Precursor Syntheses 
 
(Z)-4-(Trimethylsilyl)but-3-en-1-ol (5)2 
To a cooled solution of DiBAL (1.0 M in hexane; 90 mL, 90 mmol, 3 equiv.) in Et2O (100 mL) at 0 °C was added 4-
(trimethylsilyl)but-3-yn-1-ol (4.27 g, 30 mmol, 1 equiv.) in Et2O (35 mL) dropwise over 15 min. The reaction was 
heated at reflux overnight. After cooling to 0 °C, the reaction was quenched by the dropwise addition of aqueous 
H2SO4 (2.0 M; 120 mL) over 30 min and stirred for 45 min, warming gradually to rt. The mixture was filtered 
through celite®, diluted with Et2O (66 mL), the organic layer separated and the aqueous layer extracted 3 times 
with Et2O (40 mL). The combined organic layers were washed with ice cold water (135 mL), dried (MgSO 4), 
filtered, and the solvent was removed under reduced pressure. Purification of residues by distillation under 
reduced pressure (65 °C, 2 mmHg) yielded the title compound (3.94 g, 91 %) as a colourless oil. 1H NMR (400 
MHz, CDCl3) H = 6.16 (1H, dt, J 14.3, 7.4), 5.55 (1H, dt, J 14.3, 1.3), 3.54 (2H, d, J 6.5), 2.26 (2H, d, J 6.5), 1.50 (1H, bs), 
0.00 (9H, s); m/z (EI+) 141 (1% [C8H17Si]), 83 (25% [C6H11]), 101 (30% [C4H9OSi]), 129 (60% [C6H13OSi]), 75 (100% 
[(CH3)2HSi+]). 
(Z)-4-(Trimethylsilyl)but-3-en-1-yl 4-toluenesulfonate (6) 
According to general procedure 1, to a cooled solution of (Z)-4-(trimethylsilyl)but-3-en-1-ol 5 (2.29 g, 15.9 mmol) 
in CH2Cl2 (32 mL) were added DMAP (1.17 g, 9.54 mmol), p-TsCl (3.63 g, 19 mmol) and Et3N (2.20 mL, 15.9 mmol) 
at 0 °C after 5 h TLC analysis showed the complete consumption of starting alcohol. Work up was carried out based 
on general procedure 1. Purification of the residue by flash column chromatography (PE:Et2O 1:1) yielded the title 
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compound (4.41 g, 93%) as a colourless oil. 1H NMR (400 MHz, CDCl3) H = 7.79 (2H, d, J 7.8), 7.34 (2H, d, J 7.8), 
6.12 (1H, dt, J 14.1, 7.1), 5.64 (1H, dt, J 14.1, 1.2), 4.03 (2H, t, J 6.9), 2.50-2.45 (2H, m), 2.45 (3H, s), 0.07 (9H, s); 
m/z (EI+) 165 (10% [C4H9SO3Si]+), 283 (20% [C13H20O3SSi]+), 91 (35% [C7H7]+), 229 (100% [(C4H8)SO3C7H8]). 
 
 
N-Benzyl-N-(Z)-(4-trimethylsilylbut-3-enyl)amine (1)2,36 
Benzylamine (8.04 g, 75.00 mmol, 5 eq.) was warmed to 80 °C under nitrogen before adding a solution of (Z)-4-
(trimethylsilyl)but-3-en-1-yl 4-toluenesulfonate 6 (4.48 g, 15.00 mmol, 1 eq.) in dry ethanol (15 mL).  The resulting 
solution was stirred at 80 °C for 5 hours, when TLC showed complete consumption of starting material tosylate.  The 
ethanol was removed in vacuo and the excess of benzylamine carefully removed by distillation under reduced pressure 
(Kugelrohr, 85 °C, 20 mmHg).  The residue was partitioned between dichloromethane (60 mL) and 1.0 M aqueous 
sodium hydroxide solution (40 mL).  The organic layer was separated, the aqueous layer extracted with 
dichloromethane (3 x 10 mL), the combined organic layers dried over magnesium sulfate, filtered and concentrated in 
vacuo.  The residue was purified by flash column chromatography (90% hexane 9% ethyl acetate 1% triethylamine) to 
give the title compound 1 (2.28 g, 9.75 mmol, 65%) as a colourless oil.  max(neat)/cm-1 3313, 1606;H (300 MHz; CDCl3) 
7.36-7.21 (5H, m, H-Ar), 6.29 (1H, td, J 7.0, 14.1, H-C3), 5.58 (1H, td, J 1.2, 14.1, H-C4), 3.81 (2H, s, H-C5), 2.70 (2H, t, J 
7.0, H-C1), 2.35 (2H, ddt, J 1.2, 7.0, 7.0; H-C2), 1.36 (1H, bs, H-NH), 0.12 (9H, s, H-CTMS); C (75.5 MHz; CDCl3) 146.2 
(C3), 140.5 (ArC), 131.2 (C4), 128.4 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 54.0 (C5), 49.1 (C1), 34.1 (C2), 0.3 (CTMS). 
 
 
(Z)-4-(Trimethylsilyl)but-3-en-1-amine (7) 
NaN3 (2.93 g, 45 mmol) was added portionwise to a solution of (Z)-4-(trimethylsilyl)but-3-en-1-yl 4-
toluenesulfonate 6 (4.48 g, 15 mmol) in DMF (30 mL). The resulting solution was heated and stirred to 60 °C for 2 
h. Work up was carried out based on general procedure 3. Purification of the residue by flash column 
chromatography (PE:Et2O 9:1) yielded the )-(4-azidobut-1-en-1-yl)trimethylsilane (2.29 g, 90%) as a colourless oil. 
1H NMR (400 MHz, DMSO-d6) H = 6.15 (1H, dt, J 14.2, 1.4), 5.50 (1H, dt, J 14.2, 7.3), 3.26 (2H, t, J 6.8), 2.26 (2H, 
qd, J 6.8, 1.4), 0.00 (9H, s); m/z (EI+) 169 (1% [M]+), 126 (25% [C4H8N3Si]+), 100 (50% [C4H10NSi]+), 73 (100% 
[C3H9Si]+). 
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A solution of LiAlH4 (26.5 mL, 26.3 mmol; 1.0 M in THF) was diluted with THF (106 mL). After cooling to 0 °C, ( Z)-
(4-azidobut-1-en-1-yl)trimethylsilane (4.24 g, 25 mmol) in THF (25 mL) was added dropwise over 2 h using a syringe 
pump at a rate of 0.2 mmol per min. The mixture was stirred for 30 min at 0 °C and a solution of brine (4 mL per 
mmol) together with Et2O (2 mL per mmol) was added dropwise over 30 min. The mixture was allowed to warm 
to rt over 30 min and any precipitate was removed by filtration through Celite®. The organic layer was separated 
and the aqueous layer extracted with Et2O (3 x 1.2 mL per mmol). The combined organic solution were dried 
(MgSO4), filtered, and volatile components removed under reduced pressure to yield the pure title compound 
(3.29 g, 92%) as a clear oil and this was used without purification. 1H NMR (400 MHz, CDCl3) H = 6.28 (1H, dt, J 
14.2, 6.9), 5.61 (1H, d, J 14.2), 2.76 (2H, t, J 6.9), 2.27 (2H, qd, J 6.9, 6.9), 1.21 (2H, bs), -0.13 (9H, s); m/z (EI+) 99 
(40% [C5H11Si]+), 128 (50% [C7H16Si]+), 74 (100% [C3H10Si]+). 
 
3-Buten-1-amine hydrochloride (8) 
To a solution of 3-buten-1-ol (0.50 g, 6.93 mmol, 1 equiv.) in THF (11 mL) was added Ph3P (1.99 g, 7.62 mmol, 1.1 equiv.) 
and phthalimide (1.12 g, 7.62 mmol, 1.1 equiv.) portionwise.  This mixture was cooled to 0 °C and diisopropyl 
azodicarboxylate (1.5 mL, 7.62 mmol, 1.1 equiv.) was added dropwise over 2 min. The reaction mixture was stirred for 
3 h at 0 °C before warming to rt overnight.  n-Hexane (11 mL) was added and the suspension was filtered through 
Celite®.  The filtrate was washed sequentially with aqueous HCl (12 mL; 1.0 M) and saturated aqueous NaHCO3 (12 mL).  
The organic phase was dried (MgSO4), filtered, and concentrated under reduced pressure. Purification of the residue 
by flash column chromatography (PE:EtOAc 9:1) afforded N-(but-3-enyl)phthalimide37a white solid (1.39 g, 100%).  Mp 
149-155 °C (lit mp 144 °C); νmax(neat)/cm-1 3021, 2927, 1708, 997, 956; 1H NMR (400 MHz, CDCl3) H = 7.70-7.55 (4H, 
m), 5.66 (1H, ddt, J 17.2, 10.5, 7.0), 4.95-4.86 (2H, m),  3.63 (2H, t, J 6.8), 2.32 (2H, q, J 7.0); 13C NMR (101 MHz, CDCl3) 
C = 168.0, 134.4, 133.7, 132.0, 123.0, 117.3, 37.2, 32.7; m/z (EI+) 133 (15% [(CO)2C6H4+]), 201 (45% [M+]). 
To a solution of N-(but-3-enyl)phthalimide (1 g, 4.97 mmol) in 98% ethanol (25 mL) was added dropwise 98% 
hydrazine monohydrate (0.5 mL, 10 mmol) over 2 minutes.  The mixture was heated to 50 °C and stirred under 
nitrogen for 1 h.  During this time a white suspension formed and slowly solidified.  After cooling to rt, HCl (5 mL, 
concentrated) was added dropwise over 3 minutes and the mixture was stirred for 10 minutes.  The white 
precipitate was removed by filtration.  After concentrating under reduced pressure, the residue was dissolved in 
water and the residues removed by filtration.  The solvent was removed under reduced pressure to give the title 
compound 8 in quantitative yield as the HCl salt (0.53 g, 4.97 mmol).   νmax(neat)/cm-1 3397, 2895, 1658, 998, 924; 
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1H NMR (270 MHz, D2O) H = 5.82-5.67 (1H, m), 5.20-5.12 (2H, m), 3.04-2.99 (2H, t, J 6.7), 2.37 (2H, q, J 6.7); 13C 
NMR (270 MHz, D2O) C = 133.3, 119.1, 38.7, 31.1.  Treatment with dry triethylamine in dry dichloromethane 
followed by an aqueous was provided the free amine. 
 
 
But-3-yn-1-amine38 
To a cooled solution of 3-butyn-1-ol (5.40 mL, 71.34 mmol) in Et2O (72 mL) were added MsCl (8.15 mL, 105.13 
mmol) and Et3N (1.5 mL, 105.13 mmol) at 0 °C and the solution gradually warmed to rt overnight. Work up was 
carried out based on general procedure 1. Purification of the residues by flash column chromatography (PE:EtOAc 4:1) 
yielded but-3-yn-1-yl methanesulfonate38 (8.39 g, 89%) as a clear oil. νmax(CHCl3)/cm-1 3288 (C4), 2941 (CH), 1334 (S=O), 
1169 (S=O); 1H NMR (400 MHz, CDCl3) H = 4.26 (2H, t, J 6.9), 3.02 (3H, s), 2.64-2.60 (2H, m), 2.05 (1H, t, J 2.6); 13C NMR 
(101 MHz, CDCl3) C = 78.9, 71.2, 67.5, 37.9, 20.1; m/z (EI+) 149 (1% [M]+), 109 (45% [C2H5O3S]+), 79 (100% [CH3O2S]+). 
NaN3 (7.80 g, 120 mmol) was added portionwise to a solution of but-3-yn-1-yl methanesulfonate (7.11 g, 47.97 
mmol) in DMF (50 mL). The resulting solution was heated and stirred to 60 °C for 2 h. Work up was carried out 
based on general procedure 3, and 4-azidobut-1-yne38 (4.11 g, 90%) was isolated as a clear oil and used without 
purification. νmax(CHCl3)/cm-1 3426, 2931, 2104; 1H NMR (400 MHz, CDCl3) H = 3.37 (2H, t, J 7.0), 2.43 (2H, td, J 7.0, 2.5), 
2.02 (1H, t, J 2.5); 13C NMR (101 MHz, CDCl3) C = 80.4, 70.6, 49.8, 19.5. 
To a cooled solution of LiAlH4 (1.0 M in THF; 37.1 mL, 37.1 mmol) in THF (106 mL) was added 4-azidobut-1-yne 
(3.36 g, 35.33 mmol) in THF (35 mL) dropwise over 2 h at 0 °C. Work up was carried out based on general procedure 
5, and the title compound (0.49 g, 20%) was isolated as a clear oil and used without purification. νmax(CHCl3)/cm-1 3410, 
3293, 2924, 1556; 1H NMR (400 MHz, CDCl3) H = 2.84 (2H, t, J 6.2), 2.32 (2H, td, J 6.2, 2.6), 2.00 (1H, t, J 2.6), 1.51 (2H, 
bs); 13C NMR (101 MHz, CDCl3) C = 82.4, 69.7, 40.9, 23.4. 
 
 
2. Cyclisation Precursors 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide (11) 
According to General Procedure 2, to a stirred solution of 4,4-dimethoxybutanoic acid 9 (0.46 g, 3.10 mmol) and T3P® 
(50% in EtOAc; 2.12 mL, 3.57 mmol) in EtOAc (23 mL) were added sequentially Et3N (0.86 mL, 6.20 mmol) and N-
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homoallyl amine 5 (0.22 g, 3.10 mmol).  After overnight stirring at rt, work up was carried out based on general 
procedure 2, affording the title compound 11 (0.278 g, 65%) and this was used without any purification. νmax(neat)/cm-
1 3011, 2937, 1688, 1457, 1173, 1080; 1H NMR (400 MHz, CDCl3) H = 5.76 (1H, ddt, J 17.1, 10.5, 6.6), 5.59 (1H, bs), 5.12-
5.07 (2H, m), 4.38 (1H, t, J 5.4), 3.36-3.30 (2H, m), 3.33 (6H, s), 2.28-2.20 (4H, m), 1.96-1.91 (2H, m); 13C NMR (101 MHz, 
CDCl3) C = 172.4, 135.3, 117.0, 103.9, 53.2, 38.5, 33.3, 31.4, 28.4; m/z (EI+) 131 (30% [C6H11O3]+), 71 (100% [C4H8N]+); 
HRMS (NSI) Found (M+H+) 202.1437, C10H20 NO3 requires 202.1438. 
 
 
N-(But-3-en-1-yl)-5,5-dimethoxypentanamide (12) 
According to General Procedure 2, to a solution of 5,5-dimethoxypentanoic acid 10 (1.17 g, 7.21 mmol) and T3P® (50% 
in EtOAc; 4.93 mL, 8.29 mmol) in EtOAc (54 mL) were added sequentially Et3N (2.01 mL, 14.42 mmol) and N-homoallyl 
amine 5 (0.51 g, 7.21 mmol).  After overnight stirring at rt, work up was carried out based on general procedure 2, 
affording the title compound 12 (1.02 g, 66%) and this was used without any purification. νmax(neat)/cm-1 3296, 2936, 
2831, 1642, 1126, 1051; 1H NMR (400 MHz, CDCl3) H = 5.75 (1H, ddt, J 17.1, 10.2, 6.9), 5.55 (1H, bs), 5.12-5.05 (2H, m), 
4.35 (1H, t, J 5.4), 3.31 (2H, q, J 6.7), 3.31 (6H, s), 2.25 (2H, qt, J 6.8, 1.5), 2.18 (2H, t, J 7.3), 1.72-1.59 (4H, m); 13C NMR 
(101 MHz, CDCl3) C = 172.7, 135.5, 117.4, 104.7, 53.1, 38.5, 36.5, 34.0, 32.1, 21.0; m/z (EI+) 215 (1% [M]+), 184 (20% 
[C10H18NO2]+), 113 (35% [C6H10NO]+), 71 (100% [C4H8N]+); HRMS (NSI) Found (M+H+) 216.1595, C11H22NO3 requires 
216.1594. 
 
 
(Z)-4,4-Dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)butanamide (13) 
According to General Procedure 2, to a solution of 4,4-dimethoxybutanoic acid 9 (0.20 mL, 1.33 mmol) and T3P® (50% 
in EtOAc; 0.91 mL, 1.53 mmol) in EtOAc (10 mL) were added sequentially Et3N (0.37 mL, 2.66 mmol) and (Z)-4-
(trimethylsilyl)but-3-en-1-amine 7 (0.19 g, 1.33 mmol).  After overnight stirring at rt, work up was carried out based on 
general procedure 2, affording the title compound 13 (0.15 g, 41%) and this was used without any purification. 
νmax(CHCl3)/cm-1 3296, 2955, 1647, 1250, 1061; 1H NMR (400 MHz, CDCl3) H = 6.22 (1H, dt, J 14.4, 7.3), 5.64 (1H, td, J 
14.4, 1.3), 5.59 (1H, bs), 4.38 (1H, t, J 5.6), 3.39-3.24 (2H, m), 3.32 (6H, s), 2.33 (2H, q, J 6.7), 2.23-2.19 (2H, m), 1.96-
1.91 (2H, m), 0.12 (9H, s); 13C NMR (101 MHz, CDCl3) C = 172.6, 144.9, 132.8, 104.1, 53.5, 39.2, 33.5, 31.7, 28.6, 0.5; 
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m/z (EI+) 273 (1% [M]+), 128 (50% [C6H14NSi]+), 73 (65% [C3H9Si]+), 71 (100% [C4H8N]+); HRMS (APCI) Found (M+H+) 
274.1832, C13H28NO3Si requires 274.1833. 
 
 
(Z)-5,5-Dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)pentanamide (14) 
According to General Procedure 2, to a solution of 5,5-dimethoxypentanoic acid 10 (0.43 g, 2.65 mmol) and T3P® (50% 
in EtOAc; 1.82 mL, 3.05 mmol) in EtOAc (15 mL) were added sequentially Et3N (0.74 mL, 5.30 mmol) and (Z)-4-
(trimethylsilyl)but-3-en-1-amine 7 (0.38 g, 2.65 mmol).  After overnight stirring at rt, work up was carried out based on 
general procedure 2, affording the title compound 14 (0.39 g, 51%) and this was used without any purification. 1H NMR 
(400 MHz, CDCl3) H = 6.23 (1H, dt, J 14.2, 7.3), 5.65 (1H, dt, J 14.2, 1.3), 5.50 (1H, bs), 4.36 (1H, t, J 5.4), 3.35-3.30 (2H, 
m), 3.31 (6H, s), 2.33 (2H, qd, J 6.9, 1.3), 2.18 (2H, t, J 7.3), 1.73-1.60 (4H, m), 0.12 (9H, s); 13C NMR (101 MHz, CDCl3) C 
= 172.7, 145.0, 132.8, 104.7, 53.1, 39.1, 36.5, 33.6, 32.2, 21.0, 0.42; m/z (EI+) 287 (1% [M]+), 142 (35% [C7H16NSi]+), 71 
(100% [C4H8N]+). 
 
 
(Z)-5,5-Dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)pentanamine (16). 
A solution of (Z)-5,5-dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)pentanamide (14) (575 mg, 2.00 mmol, 1.00 eq.) in 
tetrahydrofuran (4 mL) was added dropwise at room temperature to a stirred suspension of lithium aluminium hydride 
(80 mg, 2.10 mmol, 1.05 eq.) in tetrahydrofuran (4.2 mL).  The reaction was heated to 60 °C for 5 hours.  After this time 
the solution was cooled to room temperature and quenched with a saturated aqueous solution of sodium chloride (10 
mL) and diluted with diethyl ether (5 mL).  Aluminum salts were then removed by filtration through a pad of celite.  The 
organic layer was separated and the aqueous layer extracted with diethyl ether (3 x 5 mL).  The combined organic layers 
were dried over sodium sulfate, filtered and concentrated in vacuo.  The pale yellow residue was purified by a short 
flash column chromatography (100% ethyl acetate) to afford the title compound 16 (493 mg , 1.80 mmol, 90%) as a 
colourless oil.  max(neat)/cm-1 3318, 2950, 2828, 1606, 857; H (400 MHz; CDCl3) 6.26 (1H, td, J 7.2, 14.4, H-C3), 5.57 
(1H, td, J 1.2, 14.4, H-C4), 4.35 (1H, t, J 5.6, H-C9), 3.30 (6H, s, H-C10), 2.66 (2H, t, J 7.2, H-C1), 2.61 (2H, t, J 7.2, H-C5), 
2.33 (2H, ddt, J 1.2, 7.2, 7.2, H-C2), 1.74 (1H, bs, H-NH), 1.63 (2H, m, H-C8), 1.55-1.48 (2H, m, H-C6), 1.40-1.33 (2H, m, 
H-C7), 0.11 (9H, s, H-CTMS); C (100.6 MHz; CDCl3) 146.3 (C3), 131.2 (C4), 104.5 (C9), 52.8 (C10), 50.0 (C5), 49.8 (C1), 
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34.1 (C2), 32.5 (C8), 30.0 (C6), 22.5 (C7), 0.3 (CTMS); m/z (CI) 274 (MH+, 57), 242 (14), 86 (100); HRMS (CI) Found (M+H+) 
274.2202, C14H32NO2Si requires 274.2202. 
 
 
N-(But-3-yn-1-yl)-4,4-dimethoxybutanamide (17) 
To but-3-yn-1-amine (0.31 g, 4.48 mmol, 1 equiv.) in EtOAc (8 mL) was sequentially added 2,5-dioxopyrrolidin-1-yloxy 
4,4-dimethoxybutanoate (1.10 g, 4.48 mmol, 1 equiv.) and N,N′-dicyclohexylcarbodiimide (0.93 g, 4.48 mmol, 1 equiv.) 
portionwise. The mixture was stirred at rt overnight and the precipitate was filtered. The filtrate was washed with 
saturated aqueous NaHCO3 (2 x 10 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. Purification 
of the residues by flash column chromatography (EtOAc:CH2Cl2 1:4) yielded the title compound 16 (0.52 g, 59%) as a 
clear oil.  νmax(neat)/cm-1 3291, 3084, 2939, 1721, 1125, 1054; 1H NMR (400 MHz, CDCl3) H = 6.12 (1H, bs), 4.35 (1H, t, 
J 5.3), 3.35 (2H, q, J 5.3), 3.29 (6H, bs), 2.37-2.34 (2H, m), 2.22 (2H, bt, J 7.3), 1.97 (1H, bt, J 2.5), 1.92-1.87 (2H, m); 13C 
NMR (101 MHz, CDCl3) C = 172.7, 104.1, 81.8, 70.1, 53.5, 38.1, 31.4, 28.4, 19.5; m/z (EI+) 169 (20% [C9H15NO2]+), 125 
(50% [C7H11NO]+); HRMS (NSI) Found (M+Na+) 222.1099, C10H17NO3Na requires 222.1101. 
 
 
N-(But-3-yn-1-yl)-5,5-dimethoxypentanamide (18) 
To a solution of 5,5-dimethoxypentanoic acid 10 (0.070 g, 0.43 mmol) and T3P® (50% in EtOAc; 0.29 mL, 0.49 mmol) in 
EtOAc (3.2 mL) were added sequentially Et3N (0.12 mL, 0.86 mmol) and but-3-yn-1-amine (0.030 g, 0.43 mmol). After 
overnight stirring at rt, work up was carried out based on general procedure 2, affording the title compound 17 (0.052 
g, 57%) and this was used without any purification.  νmax(neat)/cm-1 3308, 3011, 1666, 1257, 1166; 1H NMR (400 MHz, 
CDCl3) H = 5.89 (1H, bs), 4.35 (1H, t, J 5.4), 3.34 (2H, q, J 6.4), 3.31 (6H, s), 2.39 (2H, td, J 6.4, 2.6), 2.21 (2H, t, J 7.2), 
2.00 (1H, t, J 2.6), 1.74-1.60 (4H, m); 13C NMR (101 MHz, CDCl3) C = 172.9, 104.6, 81.8, 70.1, 53.1, 38.1, 36.3, 32.0, 20.9, 
19.7; m/z (EI+) 213 (1% [M]+); HRMS (NSI) Found (M+H+) 214.1438, C11H20NO3 requires 214.1438. 
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3. Aza-Silyl-Prins Inter- and Intramolecular Cyclisations 
 
(±)-1-Benzyl-6-pentyl-1,2,3,6-tetrahydropyridine (3)2 
Following the general procedure 4, N-benzyl-N-Z-(4-trimethylsilylbut-3-enyl)amine 1 (234 mg, 1.00 mmol), in the 
presence of 1,1-dimethoxyhexane (0.146 g, 172 μL, 1.00 mmol), disappeared on TLC after 12 hours of stirring at reflux 
temperature.  The work up gave a brown oil, which was purified by flash column chromatography (96% hexane 3% 
ethyl acetate 1% triethylamine) to give the title compound 3 (182 mg, 75%) as a yellow oil.  max(neat)/cm-1 3027, 2929, 
2869, 1662; H (400 MHz; CDCl3) 7.37-7.24 (5H, m), 5.81-5.77 (1H, m), 5.65-5.61 (1H, m), 3.94 (1H, d, J 13.6), 3.40 (1H, 
d, J 13.6), 2.93-2.86 (2H, m), 2.40-2.36 (1H, m), 1.05-2.98 (2H, m), 1.63-1.55 (2H, m), 1.34-1.22 (6H, m), 0.89 (3H, t, J 
6.5); C (100.6 MHz; CDCl3) 139.8, 130.2, 129.0, 128.2, 126.9, 125.1, 59.0, 58.2, 46.3, 33.4, 32.3, 25.1, 24.1, 22.8 , 14.2; 
m/z (CI) 244 (MH+, 100), 172 (70), 120 (15); HRMS (CI) Found (MH+) 244.2065, C17H26N requires 244.2063. 
 
 
Table 1 entry 2:  1,5,6,8a-Tetrahydroindolizin-3(2H)-one (19)36 
According to General Procedure 4, a suspension of Sc(OTf)3 (0.08 g, 0.16 mmol) in MeCN (3.5 mL) was heated to 
reflux for 5 min.  A solution of (Z)-4,4-dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)butanamide 13 (0.05 g, 0.16 
mmol) in MeCN (1.5 mL) was added dropwise over 1 min to the mixture.  The suspension was stirred for 48 h. 
Work up was carried out based on general procedure 4.  Purification of the residues by flash column 
chromatography (EtOAc:CH2Cl2 4:1) yielded the title compound 19 (0.0169 g, 75%) as a colourless oil. 
νmax(CHCl3)/cm-1 2927, 1665; 1H NMR (400 MHz, CDCl3) H = 5.79-5.75 (1H, m), 5.68-5.65 (1H, dm, J 10.2), 4.19 (1H, 
dd, J 13.4, 6.8), 4.12 (1H, bs), 2.84 (1H, td, J 12.3, 5.0), 2.50-2.34 (2H, m), 2.27-2.19 (2H, m), 2.08-2.02 (1H, dm, J 
17.8), 1.63-1.53 (1H, m); 13C NMR (101 MHz, CDCl3) C = 173.2, 128.5, 125.2, 55.1, 36.4, 31.9, 26.5, 24.7; m/z (EI+) 
137 (100% [M]+); HRMS (APCI) Found (M+H+) 138.0914, C8H12NO requires 138.0913.  
 
 
Table 1 Entry 5:  2,3,6,7-Tetrahydro-1H-quinolizin-4(9aH)-one (20)36 
According to General Procedure 4, a suspension of Sc(OTf)3 (0.34 g, 0.70 mmol) in MeCN (3.5 mL) was heated to 
reflux for 5 min. A solution of (Z)-5,5-dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)pentanamide 14 (0.20 g, 0.70 
25 
mmol) in MeCN (1.5 mL) was added dropwise over 1 min to the mixture. The suspension was stirred for 48 h.  
Work up was carried out based on general procedure 4. Purification of the residues by flash column 
chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 20 (0.068 g, 64%) as a colourless oil.  1H NMR (400 
MHz, CDCl3) H = 5.84-5.79 (1H, m), 5.50 (1H, ddt, J 10.0, 2.8, 1.4), 4.81 (1H, ddt, J 12.5, 5.7, 1.1), 3.99-3.94 (1H, 
m), 2.58 (1H, td, J 12.5, 4.0), 2.50-2.43 (1H, m), 2.36-2.30 (1H, m), 2.28-2.18 (1H, m), 2.03-1.96 (2H, m), 1.87-1.80 
(1H, m), 1.67 (1H, dddd, J 13.0, 5.6, 2.9, 1.1), 1.40 (1H, tdd, J 13.0, 11.4, 3.2); 13C NMR (101 MHz, CDCl3) C = 169.0, 
129.1, 126.0, 55.3, 38.4, 32.6, 30.4, 25.3, 19.9; m/z (EI+) 151 (100% [M]+); HRMS (APCI) Found (M+H+) 152.1069, 
C9H14NO requires 152.1070.  
 
 
4. Aza-Prins Intramolecular Cyclisations 
 
Table 2 Entry 1:  (7R*,8aR*)-7-Chlorohexahydroindolizin-3(2H)-one (21a) 
According to General Procedure 5, N-(but-3-en-1-yl)-4,4-dimethoxybutanamide 11 (0.11 g, 0.55 mmol) was mixed with 
CH2Cl2 (5 mL) for 5 min and FeCl3 (0.09 g, 0.55 mmol) was added.  The mixture was stirred for 48 h.  Work up was carried 
out based on general procedure 5.  Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) 
yielded the title compound 21a (0.08 g, 94%) as a clear oil. νmax(CHCl3)/cm-1 1673, 748; 1H NMR (700 MHz, CDCl3) H = 
4.16 (1H, dd, J 13.6, 5.1), 3.93 (1H, tt, J 12.0, 3.8), 3.48 (1H, dtd, J 11.0, 7.2, 3.4), 2.66 (1H, td, J 13.3, 3.1), 2.40-2.32 (3H, 
m), 2.24-2.19 (1H, m), 2.17-2.15 (1H, dm, J 13.3), 1.67-1.60 (2H, m), 1.49 (1H, q, J 12.0); 13C NMR (176 MHz, CDCl3) C = 
173.5, 56.5, 55.4, 43.9, 39.0, 35.3, 30.2, 24.6; m/z (EI+) 173 (25% [M]+), 138 (100% [C8H12NO]+); HRMS (NSI) Found 
(M+H+) 174.0679, C8H1335ClNO requires 174.0680. 
 
 
Table 2 Entry 3:  (7R*,8aR*)-7-Bromohexahydroindolizin-3(2H)-one (21b) 
According to General Procedure 5, N-(but-3-en-1-yl)-4,4-dimethoxybutanamide 11 (0.13 g, 0.63 mmol) was mixed with 
CH2Br2 (5 mL) for 5 min and BBr3 (1.0 M in CH2Cl2; 0.63 g, 0.63 mmol) was added. The mixture was stirred for 48 h. Work 
up was carried out based on general procedure 5. Purification of the residues by flash column chromatography 
(EtOAc:CH2Cl2 1:1) yielded the title compound 21b (0.070 g, 51%) as a clear oil. νmax(CHCl3)/cm-1 1673, 651; 1H NMR (400 
26 
MHz, CDCl3) H = 4.05-4.00 (1H, m), 3.94 (1H, dtd, J 10.8, 7.4, 3.5), 3.12 (1H, td, J 12.8, 3.3), 2.41-2.36 (1H, m), 2.28-2.22 
(2H, m), 2.02-1.99 (1H, m), 1.86-1.80 (1H, m), 1.67-1.56 (3H, m); 13C NMR (101 MHz, CDCl3) C = 173.8, 52.0, 49.8, 41.0, 
35.6, 32.6, 29.1, 24.5; m/z (EI+) 217 (5% [M-H]+), 138 (100% [C8H12NO]+); HRMS (EI) Found (M+) 217.0096, C8H1279BrNO 
requires 217.0097. 
 
 
Table 2 Entry 5:  Cis and Trans 7-Fluorohexahydroindolizin-3(2H)-one (21c) 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide 11 (0.20 g, 0.99 mmol) was mixed with PhH (5 mL) for 5 min and 
BF3.OEt2 (0.13 mL, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on 
general procedure 5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded a mixture 
of the title compounds (0.056 g, 36%) as a clear oil, in a mixture of diastereomers of ratio 1:1. νmax(CHCl3)/cm-1 1677, 
1422; cis- isomer (7R*,8aR*)-7-Fluorohexahydroindolizin-3(2H)-one 1H NMR (400 MHz, CDCl3) H = 5.02-4.88 (1H, 
dm, JHF 47.0), 4.15 (1H, dddd, J 13.8, 5.7, 3.8, 1.5), 3.49-3.42 (1H, m), 2.62-2.55 (1H, tm, J 13.2), 2.37-2.30 (1H, m), 
2.23-2.15 (3H, m), 1.96 (1H, ddtd, J 16.5, 7.6, 3.8, 1.6), 1.67-1.57 (1H, m), 1.54-1.42 (1H, m), 1.38-1.20 (1H, m); 13C 
NMR (101 MHz, CDCl3) C = 173.8, 87.1 (d, JCF 169.6), 51.4, 38.1 (d, JCF 20.9), 36.8 (d, JCF 13.9), 30.3), 29.4 (d, JCF 
20.6), 25.1; trans- isomer (7R*,8aS*)-7-Fluorohexahydroindolizin-3(2H)-one 1H NMR (400 MHz, CDCl3) H = 4.58 
(1H, dtt, JHF 47.8, 11.3, 4.4), 3.98 (1H, ddd, J 13.8, 6.1, 1.1), 3.75 (1H, dtd, J 11.5, 7.1, 3.7), 2.95 (1H, dt, J 13.3, 3.6), 
2.37-2.30 (2H, m), 2.28-2.24 (1H, m), 2.11-2.03 (1H, m), 1.67-1.57 (1H, m), 1.54-1.42 (2H, m), 1.38-1.20 (1H, m); 
13C NMR (101 MHz, CDCl3) C = 173.6, 89.7 (d, JCF 175.8), 55.1 (d, JCF 12.5), 39.5 (d, JCF 18.1), 34.6 (d, JCF 2.1), 31.2 
(d, JCF 19.5), 30.4, 24.7; 19F NMR (377 MHz, CDCl3), F = −173.0 and −189.7; m/z (EI+) 157 (100% [M]+); HRMS (APCI) 
Found (M+H+) 158.0973, C8H13FNO requires 158.0976. 
 
 
Table 2 Entry 8:  (8R*,9aR*)-8-Chlorohexahydro-1H-quinolizin-4(6H)-one (22a) 
N-(But-3-en-1-yl)-5,5-dimethoxypentanamide 12 (0.21 g, 0.99 mmol) was mixed with CH2Cl2 (5 mL) for 5 min and FeCl3 
(0.16 g, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 22a (0.16 
g, 86%) as a clear oil. νmax(CHCl3)/cm-1 1626, 745; 1H NMR (600 MHz, CDCl3) H = 4.80 (1H, ddd, J 13.7, 4.6, 2.5), 3.93 
(1H, tt, J 11.8, 4.4), 3.27 (1H, dddd, J 11.3, 8.4, 5.6, 2.4), 2.42 (1H, td, J 13.7, 2.7), 2.40-2.34 (1H, dtm, J 17.1, 5.0), 2.29 
27 
(1H, ddd, J 17.4, 9.6, 5.6), 2.20-2.13 (2H, m), 1.99-1.95 (1H, m), 1.82-1.77 (1H, m), 1.68-1.57 (3H, m), 1.51 (1H, dddd, J 
19.0, 11.1, 8.1, 3.2); 13C NMR (101 MHz, CDCl3) C = 169.6, 56.1, 56.0, 44.3, 41.7, 36.2, 33.1, 30.2, 19.6; m/z (EI+) 187 
(25% [M]+), 152 (100% [C9H14NO]+); HRMS (EI) Found (M+) 187.0759, C9H1435ClNO requires 187.0758. 
 
 
Table 2 Entry 10:  (8R*,9aR*)-8-Bromohexahydro-1H-quinolizin-4(6H)-one (22b) 
N-(But-3-en-1-yl)-5,5-dimethoxypentanamide 12 (0.21 g, 0.99 mmol) was mixed with CH2Br2 (5 mL) for 5 min and InBr3 
(0.55 g, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 22b (0.22 
g, 86%). νmax(CHCl3)/cm-1 1628, 647; 1H NMR (400 MHz, CDCl3) H =  4.73 (1H, ddd, J 13.8, 4.7, 2.6), 4.03 (1H, tt, J 12.1, 
4.4), 3.24 (1H, dddd, J 11.2, 8.3, 5.5, 2.4), 2.40 (1H, td, J 13.5, 2.7), 2.35-2.20 (4H, m, H-C3, H-C7 and H-C9), 1.97-1.91 
(1H, m), 1.81-1.74 (3H, m), 1.69-1.57 (1H, m), 1.53-1.42 (1H, m); 13C NMR (101 MHz, CDCl3) C = 169.4, 56.9, 46.7, 44.9, 
42.6, 36.9, 32.9, 29.9, 19.3; m/z (EI+) 232 (5% [M]+), 152 (100% [C9H14NO]+); HRMS (APCI) Found (M+H+) 232.0332, 
C9H1579BrNO requires 232.0332. 
 
 
Table 2 Entry 11:  Cis- and trans 8-Fluorohexahydro-1H-quinolizin-4(6H)-one (22c) 
N-(But-3-en-1-yl)-5,5-dimethoxypentanamide 12 (0.21 g, 0.99 mmol) was mixed with PhH (5 mL) for 5 min and 
BF3.OEt2 (0.13 mL, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on 
general procedure 5. Purification of the residues by flash column chromatography (EtOAc:CHCl3 2:3) yielded a mixture 
of the title compounds and its isomer (0.056 g, 33%) as a colourless oil. νmax(CHCl3)/cm-1 1617, 1419, 1267; cis- isomer 
(8R*,9aR*)-8-fluorohexahydro-1H-quinolizin-4(6H)-one 1H NMR (400 MHz, CDCl3) H = 4.65 (1H, ddd, J 13.5, 5.4, 
1.7), 4.63 (1H, dtt, JHF 48.8, 11.0, 4.9), 3.31-3.24 (1H, m), 2.81 (1H, td, J 13.5, 2.8), 2.39-2.27 (2H, m), 2.18-2.06 
(2H, m), 2.05-1.95 (2H, m), 1.87-1.76 (1H, m), 1.73-1.65 (1H, m), 1.61-1.55 (1H, m), 1.54-1.42 (1H, m); 13C NMR 
(101 MHz, CDCl3) C = 169.6, 89.8 (d, JCF 176.3), 54.0 (d, JCF 12.7), 40.1 (d, JCF 16.3), 36.5, 33.0, 32.0 (d, JCF 18.6), 
30.3, 19.2; trans- isomer (8R*,9aS*)-8-fluorohexahydro-1H-quinolizin-4(6H)-one  1H NMR (400 MHz, CDCl3) H = 
5.03-4.89 (1H, dm, JHF 47.9), 4.85 (1H, dtd, J 13.8, 4.8, 2.7), 3.69-3.62 (1H, m), 2.46-2.39 (1H, m), 2.39-2.27 (2H, 
m), 2.18-2.06 (1H, m), 2.05-1.95 (2H, m), 1.87-1.76 (2H, m), 1.61-1.55 (2H, m), 1.54-1.42 (1H, m); 13C NMR (101 
MHz, CDCl3) C = 169.6, 87.1 (d, JCF 168.8), 50.8, 39.5 (d, JCF 13.0), 38.6 (d, JCF 20.6), 33.1, 30.3 (d, JCF 20.8), 29.9, 
28 
19.6; 19F NMR (377 MHz, CDCl3), F = −172.0 and −187.1; m/z (EI+) 151 (45% [C9H15FN]+), 171 (80% [M]+); HRMS (APCI) 
Found (M+H+) 172.1131, C9H15FNO requires 172.1132.  
 
 
1-(But-3-yn-1-yl)-5-methoxypyrrolidin-2’-one (28) 
N-(But-3-yn-1-yl)-4,4-dimethoxybutanamide 17 (0.07 g, 0.37 mmol) was mixed with CH2Cl2 (5 mL) for 5 min and FeCl3 
(0.06 g, 0.37 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 28 
(0.015 g, 24%) as a clear oil. νmax(CHCl3)/cm-1 3289, 2942, 1660, 1283; 1H NMR (400 MHz, CDCl3) H = 5.08 (1H, dd, J 6.3, 
1.3), 3.64 (1H, ddd, J 14.0, 7.6, 5.7), 3.32 (1H, dt, J 14.0, 7.6), 3.28 (3H, s), 2.58-2.46 (2H, m), 2.46-2.38 (1H, m), 2.33 (1H, 
ddd, J 16.7, 10.0, 3.0), 2.21-2.11 (1H, m), 2.03-1.99 (1H, dm, J 9.7), 1.97 (1H, t, J 2.7); 13C NMR (101 MHz, CDCl3) C = 
175.3, 90.9, 81.8, 69.9, 53.2, 39.7, 29.0, 24.1, 18.2; m/z (EI+) 167 (25% [M]+), 68 (100% [C4H6N]+); HRMS (APCI) Found 
(M+H+) 168.1018, C9H14NO2 requires 168.1019.  
 
 
1-(But-3-yn-1-yl)-5-methoxy-1H-pyrrol-2’(5H)-one (29)  
N-(But-3-yn-1-yl)-4,4-dimethoxybutanamide 17 (0.074 g, 0.37 mmol) was mixed with CH2Cl2 (5 mL) for 5 min and FeCl3 
(0.060 g, 0.37 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 29 
(0.0024 g, 4%) as a clear oil.  νmax(CHCl3)/cm-1 3286, 2932, 1697, 1093; 1H NMR (400 MHz, CDCl3) H = 6.90 (1H, dd, J 6.1, 
1.6), 6.28 (1H, dd, J 6.1, 0.9), 5.64 (1H, bs), 3.75 (1H, ddd, J 13.6, 7.1, 5.9), 3.34 (1H, dt, J 13.6, 7.1), 3.12 (3H, s), 2.60-
2.43 (2H, m), 1.98 (1H, t, J 2.7); 13C NMR (101 MHz, CDCl3) C = 173.7, 144.0, 130.7, 88.7, 81.5, 70.2, 50.8, 38.3, 18.6; 
m/z (EI+) 150 (5% [C9H11NO]+), 96 (75% [C7H6NO]+); HRMS (APCI) Found (M+H+) 166.0860, C9H12NO2 requires 166.0863. 
 
 
1-(But-3-en-1-yl)-5-methoxypyrrolidin-2’-one (26) 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide 15 (0.20 g, 0.99 mmol) was mixed with CH2Cl2 (5 mL) for 5 min and InCl3 
(0.35 g, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
29 
5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 26 (0.025 
g, 15%) as a clear oil.  νmax(CHCl3)/cm-1 3009, 1696, 1079; 1H NMR (400 MHz, CDCl3) H = 5.76 (1H, ddt, J 17.1, 10.3, 6.8), 
5.10-5.00 (2H, m), 4.94 (1H, dd, J 6.4, 1.4), 3.59 (1H, ddd, J 13.8, 8.0, 7.1), 3.25 (3H, s), 3.17-3.10 (1H, m), 2.49 (1H, dd, 
J 17.5, 8.8), 2.36-2.26 (3H, m), 2.10 (1H, ddd, J 10.0, 8.5, 6.4), 1.97 (1H, ddd, J 14.2, 3.2, 1.4); 13C NMR (101 MHz, CDCl3) 
C = 175.3, 135.5, 117.0, 90.3, 52.8, 40.0, 32.2, 29.2, 23.9; m/z (EI+) 169 (5% [M]+), 138 (25% [C8H12NO]+), 68 (100% 
[C4H6N]+); HRMS (EI) Found (M+) 169.1096, C9H15NO2 requires 169.1097. 
 
 
1-(But-3-en-1-yl)-5-hydroxypyrrolidin-2’-one (27) 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide 15 (0.20 g, 0.99 mmol) was mixed with CH2Cl2 (5 mL) for 5 min and InCl3 
(0.35 g, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 27 (0.011 
g, 7%) as a clear oil. νmax(CHCl3)/cm-1 3344, 2979, 1667, 1464; 1H NMR (600 MHz, CDCl3) H = 5.77 (1H, ddt, J 17.1, 10.2, 
7.0), 5.22-5.20 (1H, m), 5.08 (1H, dt, J 17.1, 1.6), 5.05-5.03 (1H, dm, J 10.2), 3.54 (1H, dt, J 13.8, 7.5), 3.28-3.23 (1H, dm, 
13.8), 3.41 (1H, d, J 8.1), 2.58-2.51 (1H, m), 2.38-2.26 (4H, m), 1.91-1.87 (1H, m); 13C NMR (101 MHz, CDCl3) C = 175.0, 
135.7, 117.2, 83.6, 39.6, 32.4, 29.1, 28.6; m/z (EI+) 68 (45% [C4H6N]+), 137 (25% [C8H11NO]+), 96 (100% [C5H6NO]+); HRMS 
(EI) Found (M+-H2O) 137.0834, C8H11NO requires 137.0835. 
 
 
Table 3 Entry 1:  (7R*,8aR*)-7-Phenylhexahydroindolizin-3(2H)-one (30a)21 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide 11 (0.20 g, 0.99 mmol) was mixed with PhH (5 mL) for 5 min and BF3.OEt2 
(0.13 mL, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 30a 
(0.043 g, 20%) as a clear oil. νmax(CHCl3)/cm-1 2936, 1672; 1H NMR (400 MHz, CDCl3) H = 7.33-7.29 (2H, m), 7.23-7.17 
(3H, m), 4.25 (1H, ddd, J 13.4, 5.0, 1.8), 3.59 (1H, dtd, J 10.9, 7.3, 3.5), 2.79 (1H, td, J 13.0, 3.5), 2.72 (1H, dt, J 12.4, 3.2), 
2.43-2.38 (2H, m), 2.29-2.20 (1H, m), 2.09-2.04 (1H, dm, J 12.9), 1.90-1.85 (1H, dm, J 13.3), 1.69-1.61 (1H, m), 1.57 (1H, 
qd, J 12.7, 4.9), 1.38 (1H, q, J 12.0); 13C NMR (101 MHz, CDCl3) C = 173.7, 145.2, 128.8, 126.8, 126.7, 57.4, 42.1, 41.2, 
30 
40.1, 32.2, 30.5, 25.3; m/z (EI+) 137 (45% [C8H11NO]+), 215 (60% [M]+); HRMS (NSI) Found (M+H+) 216.1382, C14H18NO 
requires 216.1383.  
 
 
Table 3 Entry 2:  (7R*,8aR*)-N-(3-Oxooctahydroindolizin-7-yl)acetamide (30b)21 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide 11 (0.14 g, 0.69 mmol) was mixed with MeCN (5 mL) for 5 min and 
BF3.OEt2 (0.09 mL, 0.69 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general 
procedure 5, the title compound 30b (0.003 g, 2%) was isolated as a clear oil without purification. νmax(CHCl3)/cm-1 3293, 
1656; 1H NMR (400 MHz, CDCl3) H = 5.33 (1H, bs), 4.17 (1H, ddd, J 13.4, 5.2, 1.9), 3.99 (1H, dtt, J 15.7, 11.8, 3.9), 3.57 
(1H, dtd, J 10.9, 7.5, 3.3), 2.75 (1H, td, J 13.4, 3.4), 2.40-2.36 (2H, m), 2.27-2.26 (1H, m), 2.24-2.19 (1H, m), 1.98 (3H, s), 
1.99-1.93 (1H, m), 1.64-1.55 (1H, m), 1.26-1.17 (1H, m), 1.02 (1H, q, J 11.5); 13C NMR (101 MHz, CDCl3) C = 173.7, 169.7, 
56.0, 46.7, 40.3, 38.5, 31.3, 30.4, 24.9, 23.7; m/z (EI+) 196 (65% [M]+), 137 (100% [C8H11NO]+); HRMS (EI) Found (M+) 
196.1204, C10H16N2O2 requires 196.1206.  
 
 
Table 3 Entry 2:  (7R*,8aR*)-7-Aminohexahydroindolizin-3(2H)-one (30c) 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide 11 (0.14 g, 0.69 mmol) was mixed with MeCN (5 mL) for 5 min and 
BF3.OEt2 (0.09 mL, 0.69 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general 
procedure 5. Upon separation from the organic layer, the aqueous layer was saturated by the addition of K2CO3, and 
extracted with CHCl3 (3 x 4 mL). The CHCl3 extracts were combined and washed with brine (4 mL), dried (MgSO4), 
filtered, and volatiles were evaporated under reduced pressure to yield the title compound 30c (0.043 g, 40%) as a clear 
oil. νmax(CHCl3)/cm-1 3300 (NH), 3286 (NH), 1663 (C=O); 1H NMR (400 MHz, CDCl3) H = 4.13 (1H, ddd, J 13.4, 5.2, 1.8), 
3.48 (1H, dtd, J 10.8, 7.4, 3.4), 2.86 (1H, tt, J 11.3, 3.7), 2.65 (1H, td, J 13.4, 3.3), 2.39-2.34 (2H, m), 2.24-2.16 (1H, m), 
2.05-2.00 (1H, dm, J 12.6), 1.86-1.80 (1H, dm, J 12.8), 1.65-1.55 (1H, m), 1.34 (2H, bs), 1.23-1.11 (1H, m), 1.05-0.94 (1H, 
m); 13C NMR (101 MHz, CDCl3) C = 173.7, 56.3, 48.8, 43.7, 38.6, 35.0, 30.6, 25.1; m/z (EI+) 137 (35% [C8H11NO]+), 154 
(50% [M]+); HRMS (NSI) Found (M+H+) 155.1177, C8H15N2O requires 155.1179. 
 
 
 
31 
Table 3 Entry 3:  (7R*,8aR*)-3-Oxooctahydroindolizin-7-yl acetate (30d)39 
N-(But-3-en-1-yl)-4,4-dimethoxybutanamide 11 (0.20 g, 0.99 mmol) was mixed with EtOAc (5 mL) for 5 min and BF3.OEt2 
(0.13 mL, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
5. Purification of the residues by flash column chromatography (EtOAc:CH2Cl2 1:1) yielded the title compound 30d (0.07 
g, 40%) as a clear oil, which slowly crystallised. νmax(CHCl3)/cm-1 1730, 1683, 1241; 1H NMR (400 MHz, CDCl3) H = 4.86 
(1H, tt, J 11.4, 4.2), 4.20 (1H, ddd, J 13.5, 5.2, 1.9), 3.57 (1H, dtd, J 10.9, 7.5, 3.3), 2.72 (1H, td, J 13.5, 3.4), 2.42-2.37 
(2H, m), 2.28-2.19 (2H, m), 2.05 (3H, s), 2.03-1.97 (1H, dm, J 12.5), 1.69-1.61 (1H, m), 1.49-1.39 (1H, m), 1.33-1.19 (1H, 
m); 13C NMR (101 MHz, CDCl3) C = 173.6, 170.6, 70.6, 55.4, 39.0, 37.6, 30.4, 30.2, 24.8, 21.4; m/z (EI+) 197 (25% [M]+), 
137 (100% [C8H11NO]+); HRMS (APCI) Found (M+H+) 198.1124, C10H16NO3 requires 198.1125.  Deposited with Cambridge 
Crystallographic Data Collection 1032728. 
 
 
Table 3 Entry 4:  (8R*,9aR*)-8-Phenylhexahydro-1H-quinolizin-4(6H)-one (31a)21 
N-(But-3-en-1-yl)-5,5-dimethoxypentanamide 12 (0.21 g, 0.99 mmol) was mixed with PhH (5 mL) for 5 min and BF3.OEt2 
(0.13 mL, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general procedure 
5. Purification of the residues by flash column chromatography (EtOAc:CHCl3 2:3) yielded the title compound 31a (0.052 
g, 23%) as a colourless oil. νmax(CHCl3)/cm-1 2997, 1622; 1H NMR (600 MHz, CDCl3) H = 7.33-7.28 (2H, m), 7.23-7.18 (3H, 
m), 4.92 (1H, ddd, J 13.3, 4.2, 2.4), 3.40 (1H, dddd, J 11.2, 8.4, 5.5, 2.5), 2.76 (1H, tt, J 12.3, 3.6), 2.58 (1H, td, J 13.3, 
2.7), 2.45 (1H, dtm, J 17.5, 5.3), 2.37 (1H, ddd, J 17.5, 9.8, 5.5), 2.02 (1H, ddtd, J 13.4, 5.9, 3.1, 1.6), 1.95-1.87 (2H, m), 
1.87-1.80 (1H, m), 1.75-1.63 (1H, m), 1.63-1.45 (3H, m); 13C NMR (101 MHz, CDCl3) C = 169.5, 145.3, 128.8, 126.9, 
126.7, 56.8, 42.8, 42.4, 41.9, 33.2, 32.8, 30.6, 19.5; m/z (EI+) 151 (85% [C15H20N]+), 229 (100% [M]+); HRMS (APCI) Found 
(M+H+) 230.1539, C15H20NO requires 230.1539. 
 
Table 3 Entry 5:  (8R*,9aR*)-N-(6-oxooctahydro-1H-quinolizin-2-yl)acetamide (31b)21 
N-(But-3-en-1-yl)-5,5-dimethoxypentanamide 12 (0.21 g, 0.99 mmol) was mixed with MeCN (5 mL) for 5 min and 
BF3.OEt2 (0.13 mL, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general 
procedure 5. Purification of the residues by flash column chromatography (EtOAc:CHCl3 2:3) yielded the title compound 
31b (0.0012 g, 1%) as a colourless oil. νmax(CHCl3)/cm-1 3287, 1621; 1H NMR (600 MHz, CDCl3) H = 5.29 (1H, bs), 4.84 
(1H, ddd, J 13.5, 4.7, 2.6), 3.99 (1H, tt, J 11.8, 4.3), 3.38-3.33 (1H, m), 2.52 (1H, td, J 13.5, 2.8), 2.42 (1H, dtm, J 17.1, 
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5.4), 2.32 (1H, ddd, J 17.1, 10.2, 5.7), 2.12-2.09 (1H, dm, J 13.0), 2.01-1.95 (2H, m), 1.97 (3H, s), 1.84-1.78 (1H, m), 1.71-
1.67 (1H, m), 1.53-1.47 (1H, m), 1.30-1.21 (1H, m), 1.12 (1H, q, J 12.0); 13C NMR (151 MHz, CDCl3) C = 169.7, 169.6, 
55.3, 47.2, 41.0, 40.6, 32.0, 30.3, 33.1, 23.7, 19.5; m/z (EI+) 210 (45% [M]+), 151 (100% [C9H13NO]+); HRMS (EI) Found 
(M+) 210.1365, C11H18N2O2 requires 210.1363. 
 
Table 3 Entry 6:  (8R*,9aR*)-6-Oxooctahydro-1H-quinolizin-2-yl acetate (31c) 
N-(But-3-en-1-yl)-5,5-dimethoxypentanamide 12 (0.21 g, 0.99 mmol) was mixed with EtOAc (5 mL) for 5 min and 
BF3.OEt2 (0.13 mL, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general 
procedure 5. Purification of the residues by flash column chromatography (EtOAc:CHCl3 2:3) yielded the title compound 
31c (0.008 g, 4%) as a colourless oil. νmax(CHCl3)/cm-1 1734, 1638, 1244; 1H NMR (400 MHz, CDCl3) H = 4.88-4.80 (2H, 
m), 3.35 (1H, dddd, J 11.4, 8.1, 5.5, 2.6), 2.50 (1H, td, J 13.6, 2.6), 2.42 (1H, dtm, J 17.5, 5.0), 2.32 (1H, ddd, J 17.5, 9.6, 
5.4), 2.10-2.09 (1H, m), 2.07-1.97 (2H, m), 2.04 (3H, s), 1.88-1.79 (1H, m), 1.74-1.67 (1H, m), 1.54 (1H, dtd, J 13.5, 8.0, 
2.7), 1.49-1.40 (1H, m), 1.38 (1H, q, J 11.7); 13C NMR (101 MHz, CDCl3) C = 170.7, 169.6, 71.0, 54.6, 40.2, 39.3, 31.0, 
30.3, 33.1, 21.4, 19.6; m/z (EI+) 211 (50% [M]+), 151 (75% [C9H13NO]+); HRMS (EI) Found (M+) 211.1204, C11H17NO3 
requires 211.1203. 
 
Table 3 Entry 6:  (8R*,9aR*)-8-Hydroxyhexahydro-1H-quinolizin-4(6H)-one (31d) 
N-(But-3-en-1-yl)-5,5-dimethoxypentanamide 12 (0.21 g, 0.99 mmol) was mixed with EtOAc (5 mL) for 5 min and 
BF3.OEt2 (0.13 mL, 0.99 mmol) was added. The mixture was stirred for 48 h. Work up was carried out based on general 
procedure 5. Upon separation from the organic layer, the aqueous layer was extracted with EtOAc (3 x 4 mL). The EtOAc 
extracts were combined and washed with brine (4 mL), dried (MgSO4), filtered, and volatiles were evaporated under 
reduced pressure to yield the title compound 31d (0.009 g, 6%) as a colourless oil without purification. νmax(CHCl3)/cm-
1 3365, 1615; 1H NMR (600 MHz, CDCl3) H = 4.82 (1H, ddd, J 13.7, 4.7, 2.6), 3.79 (1H, tt, J 11.1, 4.5), 3.28 (1H, dtd, J 
14.1, 5.6, 2.6), 2.45 (1H, td, J 13.7, 2.7), 2.41-2.29 (2H, m), 2.05-1.96 (3H, m), 1.88-1.79 (1H, m), 1.75-1.63 (1H, m), 1.60-
1.51 (1H, m), 1.74 (1H, bs), 1.41-1.24 (2H, m); 13C NMR (101 MHz, CDCl3) C = 169.7, 69.0, 54.5, 43.1, 40.4, 34.8, 33.1, 
30.4, 19.6; m/z (EI+) 169 (75% [M]+), 154 (50% [C9H16NO]+); HRMS (APCI) Found (M+H+) 170.1175, C9H16NO2 requires 
170.1176. 
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2,3,9,9a-Tetrahydro-1H-quinolizin-4(8H)-one (23b)40 
A suspension of BF3.OEt2 (0.08 mL, 0.63 mmol) in cyclohexane (3.5 mL) was heated to reflux for 5 min.  A solution of 
(Z)-5,5-dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)pentamide (0.14 g, 0.63 mmol) in cyclohexane (1.5 mL) was added 
dropwise over 1 min to the mixture.  The suspension was stirred at reflux for 48 h.  The solution was cooled to room 
temperature, poured into a biphasic solution of CH2Cl2 (4 mL per mmol) and water (8 mL per mmol) and stirred for 30 
min.  The organic layer was separated and the aqueous later extracted with CH2Cl2.  The combined organic fractions 
were washed with brine (4 mL), dried (MgSO4) and concentrated in vacuo.  The residue was purified by flash column 
chromatography (EtOAc:CH2Cl2, 2:3) to give the title compound 23b in a 1:1 inseparable mixture with 19 (23a) as a 
colourless oil.  1H NMR (400 MHz, CDCl3) H = 5.78-5.72 (1H, m), 5.69-5.64 (1H, m), 4.73-4.68 (1H, m), 3.46-3.41 
(1H, m), 3.31-3.24 (1H, m), 2.39-2.36 (4H, m), 2.02-1.95 (2H, m), 1.84-1.77 (1H, m), 1.72-1.65 (1H, m); 13C NMR 
(101 MHz, CDCl3) C = 169.8, 124.4, 124.3, 52.8, 42.4, 33.1, 33.0, 29.3, 18.6. 
 
 
2,3,9,9a-Tetrahydro-1H-quinolizin-4(8H)-one (23c)41 
A suspension of BF3.OEt2 (0.08 mL, 0.63 mmol) in cyclohexane (3.5 mL) was heated to reflux for 5  min. A solution 
of (Z)-5,5-dimethoxy-N-(4-(trimethylsilyl)but-3-en-1-yl)pentanamide 13 (0.14 g, 0.63 mmol) in cyclohexane (1.5 
mL) was added dropwise over 1 min to the mixture. The suspension was stirred for 48 h. Work up was carried out 
based on general procedure 5. Purification of the residues by flash column chromatography (EtOAc:CH 2Cl2 2:3) 
yielded the title compound 23c (0.10 g, 18%) as a colourless oil. 1H NMR (400 MHz, CDCl3) H = 7.25 (1H, dm, J 8.4), 
5.12 (1H, dd, J 8.4, 1.4), 3.43 (1H, tm, J 11.4), 2.54 (1H, ddt, J = 18.0, 5.5, 2.1), 2.38 (1H, ddd, J = 18.0, 12.1, 6.5), 
2.19 (1H, m), 2.08 (1H, tt, J 5.5, 1.5), 2.02-1.86 (3H, m), 1.73 (1H, ddd, J 13.2, 5.5, 2.9), 1.63-1.45 (2H, m); 13C NMR 
(101 MHz, CDCl3) C = 161.8, 124.0, 109.8, 55.5, 32.7, 30.5, 30.3, 22.3, 20.2; m/z (EI+) 151 (100% [M]+); HRMS (APCI) 
Found (M+H+) 152.1067, C9H14NO requires 152.1070.  
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